Designing and commercializing a product for people living on less than $4 per day ..... Check our website to see how we
D-REV
annual report
2013
1
Cover: ReMotion user, Agung, meets with a prosthetist in Indonesia.
Product Manager, Garrett Spiegel at Possible Health in Nepal. 1
CEO Letter
Dear Friends,
Krista Donaldson
a quick overview of 2013
In 2013, we saw our product reach expand: Brilliance, our affordable phototherapy device scaled to seven countries, the v3 ReMotion Knee was launched for field trials in four clinics in three countries—and we have several new products and exciting iterations in Research & Development. As a product portfolio company, we believe two things: First, in the importance of focusing on solving the problem, not simply developing a product. Designing and commercializing a product for people living on less than $4 per day isn’t trivial, but the real challenge is ensuring it reaches target users, is properly used, and creates economically sustainable impact. In late 2012, Brilliance entered the market and in 2013, it scaled to seven countries. We learned, for example, the challenge of getting an Indian-made product through Pakistani customs. The key is great partners, of which D-Rev has many (see page 21), and to them we are grateful. Second, we believe in doing a few things well rather than rapidly increasing the diversity of our portfolio. While there is no shortage of problems to tackle with our target users, we will create significant and sustainable impact in mobility and neonatal health. Will we stay focused on these two areas? Yes, at least until we see patients with greater access to healthcare, and industries changing—which, excitingly, is coming sooner than many think. Our ReMotion Knee is not yet on the market (look for it in late 2014), yet we have received hundreds of requests from over 15 countries. Demand is high for affordable solutions. In 2014, look not just for new products in our neonatal jaundice line, but also in impact—we are tackling the need for greater transparency, context, and lessons learned in the social sector. The power of design is the ability to tackle and solve diverse and challenging problems. We are grateful to our incredible community. At D-Rev we often find ourselves swimming upstream in the traditional aid environment—but more and more, this is less so. We are honored and humbled by our users, partners, and supporters who enable our work to improve health and increase incomes. Thank you,
16
166
countries using D-Rev products
25th
prototypes made at D-Rev (across all projects)
BRILLIANCE
most innovative company by Fast Company
ReMotion
5,122
22,000 INR
total amputees fit
(or $400) Retail price of Brilliance vs $3,000 for comparable devices
164
newborn deaths and disabilities averted
327
number of Brilliance units installed
5,099
8,192
amputees fit with a v1 Knee
babies treated with Brilliance
5
6,905
amputees fit with a v2 Knee
babies treated who otherwise would not have received effective treatment
18
amputees fit with a v3 Knee
operating budget 2013 Budget
2014 Target
$1.4 MILLION
$1.8 Million
Krista Donaldson D-Rev CEO D-Rev 2013 Annual Report
2
www.d-rev.org
We design our products for scale to impact
1+ million people living on less than $4 per day
D-Rev’s mission is to help improve the health and incomes of people living on less than $4 per day We do this by designing and delivering world-class, market-driven products that can sustainably impact over one million people. We believe that with access to needed quality products, people can lift themselves out of poverty.
There are 4 billion people living on less than $4 per day, who engage in markets and purchase products and services that bring them value. It is rarely viable, however, for for-profit companies to develop critically needed products for these populations. D-Rev fills this gap by subsidizing R&D and working with a global network of partners to design disruptive and radically affordable products to improve health and incomes. In our delivery process, we leverage for-profit market mechanisms to ensure economic sustainability and scalable impact.
D-Rev 2013 Annual Report
3
www.d-rev.org
Product Manager Garrett Spiegel in Baglung. In 2013, we field tested a new product at clinics in Nepal. D-Rev 2013 Annual Report
4
www.d-rev.org
Our Product Pipeline Brilliance
Brilliance Pro
ReMotion Jaipur Knee V1
ReMotion Knee V3
Comet
Bullseye
scale identify
Design
deliver measure
grants
private sector
grants income
funding sources
By 2013, our products reached Colombia, Ecuador, Guatemala, Indonesia, Iraq, Liberia, Senegal, Sri Lanka, Burma, Malawi, Pakistan, Philippines, India, Tanzania, and Uganda.
D-Rev 2013 Annual Report
5
www.d-rev.org
Project Results Brilliance ReMotion Research & Development
D-Rev 2013 Annual Report
6
www.d-rev.org
Project Results
Brilliance
BRILLIANCE D-Rev’s Neonatal Jaundice Initiative aims to reduce permanent brain damage to babies from delayed jaundice diagnosis and treatment.
World-Class Treatment Brilliance meets American Academy of Pediatrics standards for effective phototherapy treatment.
Every year, at least 12 million newborns worldwide need phototherapy treatment for severe jaundice. Jaundice is no longer considered an issue in the West, but a combination of factors in low-income countries such as lack of medical care access, inadequate infrastructure, ineffective treatment, and education results in a relatively high level of preventable death and disability.
Minimal Maintenance Brilliance LEDs last 16-25x longer and consume half the power of compact fluorescent tube lights commonly used in lowresource settings.
More than 6 million newborns each year do not receive the treatment they need. Yet jaundice is easy to treat. If detected early enough, it simply requires shining a specific spectrum of blue light onto a baby’s skin for 2-3 days. D-Rev developed Brilliance— a world-class, affordable phototherapy device designed for low-resource hospitals in urban and peri-urban areas. It meets the American Academy of Pediatrics guidelines for intensive treatment and retails at 22,000 INR ($400), 90% less than the cost of comparable phototherapy devices in the market.
Affordable Price Brilliance will retail at $400 vs $3,000 for comparable phototherapy devices. Target Market Urban public hospital with a Neonatal Intensive Care Unit. Launch Brilliance went on sale in November 2012 through D-Rev partner, Phoenix Medical Systems.
highlights • First international units installed. Brilliance is now treating
Brilliance was launched on the market with our partner Phoenix Medical Systems in November 2012 and is scaling impact today.
babies in Burma, Malawi, Pakistan, Philippines, India, Tanzania and Uganda
• 303 Brilliance units installed • Conducted extensive business development fieldwork in Latin America and South East Asia to explore new markets for future Brilliance sales
8,192
6,905
164
babies treated by end of 2013
babies otherwise
deaths & disabilities averted
D-Rev 2013 Annual Report
7
www.d-rev.org
Project Results
Brilliance
next steps In 2014 we will launch Brilliance Pro on the market, which includes updates and improvements to Brilliance, and continue to scale impact around the world.
BRILLIANCE PRO
AFFORDABLE & WORLD CLASS PHOTOTHERAPY
D-Rev 2013 Annual Report
8
www.d-rev.org
Brilliance treating a newborn at a hospital in Iloilo, Philippines. D-Rev 2013 Annual Report
9
www.d-rev.org
Project Results
Remotion
REMOTION KNEE
highlights
D-Rev’s ReMotion project aims to equalize access to high quality mobility devices. There are approximately 10 million above-knee amputees in low-income countries who lack access to the high quality prosthetics that would allow them to regain freedom of mobility and return to work. Modern prosthetics are prohibitively expensive, costing thousands of dollars, and the knee joint is the most complex and expensive component of the leg prosthesis system. Existing solutions are inadequate: low cost, locally manufactured knees are often mechanically unstable and unreliable, while donated Western knees are cost-prohibitive to acquire and maintain, and often perform poorly in the more rugged environments found in resource-limited settings. The ReMotion Knee is a radically affordable polycentric knee joint that provides comparable performance to high cost devices, but was designed specifically for the unique context of our target markets and will retail for less than $80.
High Range of Motion 165-degree range enabling activities like kneeling, squatting, and biking Polycentric A higher degree of stability compared to single-axis devices, blending gait with a natural swinging motion Water Resistant Withstands humid and wet climates without rusting or swelling
D-Rev 2013 Annual Report
Durable Benchtop tested to 3-5 years of use
• Launched the v3 ReMotion Knee in April • Launched field trials of the new design at 4 clinical sites in Guatemala, India, and Indonesia
• CEO Krista Donaldson spoke about the ReMotion Knee at TEDWomen
5,122 total amputees fit by end of 2013
892
Universal integration Pyramid adapter and tube clamp allow for integration with standard prosthetics systems
v1 amputees fit in 2013
Lightweight Weighs only 0.68kg
18
Noise Dampening Reduces noise during walking
v3 amputees fit in 2013
10
www.d-rev.org
Project Results
Remotion
Three Generations of the Remotion Knee
v1 D-Rev 2013 Annual Report
v2 11
v3 www.d-rev.org
next steps In 2014 we will transfer the ReMotion Knee v3 design to manufacturing and preparing for market launch and global sales at the end of the year.
ReMotion user, Agung, in Bali, Indonesia. D-Rev 2013 Annual Report
12
www.d-rev.org
Project Results
Research & Development
RESEARCH & DEVELOPMENT D-Rev projects are user-driven, meaning that we start with a problem defined by users on-the-ground. Where is our sweet spot? We seek problem areas in which: • There is a functioning ecosystem for distributing a product to end users and providing adequate maintenance that overlaps with a high social need for people living on less than $4 per day. • There is the potential for a technology solution that fits within our scope and which could profitably retail within the acceptable price range for our target customer. • D-Rev has both design expertise and a well-developed network, or we can build one cost effectively.
As part of our suite of jaundice diagnostic and treatment technologies aimed at ending kernicterus (like Brilliance), we are currently developing two additional products:
BULLSEYE
comet
A low cost, highly accurate lightmeter so doctors who use Brilliance Pro in their hospitals and clinics can measure the dosage of jaundice treatment they are administering and effectively treat babies around the world.
Comet entered field trials in 2013 to gather extensive design and usage feedback in India, Nepal, and Kenya.
The lightmeter will launch on the market with Brilliance Pro in 2014.
D-Rev 2013 Annual Report
An extremely affordable, high performance, and compact jaundice treatment device targeted at rural and limited-infrastructure clinics and hospitals. Not every baby has access to a large public hospital. Most babies in the developing world are born at home and their parents bring them to the closest facility, a clinic. Comet addresses this market and its unique needs, by being lightweight enough to be delivered on foot to remote locations, and small enough to work in tight spaces.
The project has a seed grant from Saving Lives at Birth.
13
www.d-rev.org
our financials 2013 Revenue & expenses 2014 proposed budget why donate?
D-Rev 2013 Annual Report
14
www.d-rev.org
Our Financials
2013 Revenue & Expenses
2013 revenue & expenses 25%
6%
Bilaterals
2% 2% R&D
Impact
Fundraising
8%
General & Administrative
35%
ReMotion
13%
Individuals
13%
Comet
2%
Corporate
1%
Earned Income
59%
34%
Foundations
Brilliance
Revenue
Expenses
Form 990s are available on www.d-rev.org
D-Rev 2013 Annual Report
15
www.d-rev.org
Our Financials
2014 Proposed Budget
2014 Proposed Budget Our target budget for 2014 is $1.8 million
1%*
Impact
9%
General & Administrative
5%
Fundraising
41%
14%**
ReMotion
R&D
* Product specific Impact Assessment activities are included in each product’s proposed budget
30%
** The R&D budget includes Comet, Bullseye, and future product pipeline work
D-Rev 2013 Annual Report
Brilliance
16
www.d-rev.org
Our Financials
Why Donate
why donate? Reasons to invest—in people—through D-Rev
1
Prioritizing People We are focused on real human needs that are not being adequately addressed. Our projects are driven by users and implementers. Our products change lives. People return to work, to school, to life.
2
Impact-centric Our currency is impact. No convoluted corporate structure, no mission creep.
3
Cost-effective We leverage the market to ensure our products sustainably reach the people who need them most.
4
Economically Sustainable + Scalable Our products are sold with profit margin. This holds us accountable to our customers and results in products that scale using markets, not donors.
5
Obsessively Solving Problems We aim for nothing less than disrupting markets and changing people’s expectations of what is possible— for their healthcare, potential, and future.
6
Accountable We are transparent. Check our website to see how we use our funds and measure our impact. Have a question about how we do something? Please ask.
D-Rev 2013 Annual Report
17
www.d-rev.org
ABOUT D-REV press/major media who we are our partners
D-Rev 2013 Annual Report
18
www.d-rev.org
About D-Rev
Press/Major Media
press/major media 1,000 Knees
International Business
November 2012 Remobilizing the 9.5 Million amputees in need
January 2014 Light bulb moments for a non-profit
$80 Prosthetic Knee That’s Changing Lives
Revolutionary Design for Good
December 2014 Engineer Krista Donaldson introduces the ReMotion Knee
D-Rev 2013 Annual Report
July 2012 Designing Brilliance phototherapy in context
Brilliant Designs that Save Lives
The Top 50 Innovations of 2009
November 2013 Light Saver: D-Rev’s Brilliance Jaundice Lamp
July 2012 The $20 Knee
If Mother Theresa was a hacker
World Economic Forum
July 2013 Bringing low-cost prosthetic knees to the world
September 2013 Technology Pioneer 2014
The World’s Most Innovative Companies
The Tech Awards
February 2013 Bringing a design ethic to third-world healthcare
November 2013 Tech Awards Laureate: Brilliance
Delivering Affordable Innovation
Siemens Stiftung
February 2013 A market-driven approach to design innovation
October 2013 Empowering People Award
19
www.d-rev.org
About D-Rev
Who We Are
Who we are Our Board
Our Advisors
Our Team
D-Rev 2013 Annual Report
20
www.d-rev.org
About D-Rev
Our Partners
Our Partners Thank you to our partners. You catalyze and amplify our impact and successes.
D-Rev 2013 Annual Report
21
www.d-rev.org
Thank You!
Your support makes this possible.
695 Minnesota St. | San Francisco, CA | 94107 | USA 415 642 1143 |
[email protected] D-Rev is a 501(c)3 non-profit organization
Cover photo and page 12 photo by: Scott Erikson
www.d-rev.org
